✦ LIBER ✦

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)

✍ Scribed by Fukuoka, M.; Wu, Y.-L.; Thongprasert, S.; Sunpaweravong, P.; Leong, S.-S.; Sriuranpong, V.; Chao, T.-Y.; Nakagawa, K.; Chu, D.-T.; Saijo, N.; Duffield, E. L.; Rukazenkov, Y.; Speake, G.; Jiang, H.; Armour, A. A.; To, K.-F.; Yang, J. C.-H.; Mok, T. S. K.

Book ID: 125445249
Publisher: American Society of Clinical Oncology
Year: 2011
Tongue: English
Weight: 241 KB
Volume: 29
Category: Article
ISSN: 0732-183X
DOI: 10.1200/jco.2010.33.4235

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase III, randomized, open-label, first

Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China

✍ Yi-Long WU; Da-Tong CHU; Baohui HAN; Xuyi LIU; Li ZHANG; Caicum ZHOU; Meilin LIA 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 815 KB

Tumor response and health-related qualit

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study

✍ Wu, Yi-Long; Fukuoka, Masahiro; Mok, Tony S.K.; Saijo, Nagahiro; Thongprasert, S 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 565 KB

Weekly nab-Paclitaxel in Combination Wit

Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Final Results of a Phase III Trial

✍ Socinski, M. A.; Bondarenko, I.; Karaseva, N. A.; Makhson, A. M.; Vynnychenko, I 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 207 KB

OP78 EGFR mutations based on circulating

OP78 EGFR mutations based on circulating free DNA (cfDNA) in the subset of Japanese patients (pts) from IPASS (IRESSA Pan ASia Study), a Phase III study of first-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients with advanced non-small-cell lung cancer (NSCLC)

✍ N. Yamamoto; Y. Ichinose; Y. Nishiwaki; Y. Ohe; K. Nishio; H. Jiang; E. Duffield 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 40 KB

9165 Motesanib or bevacizumab in combina

9165 Motesanib or bevacizumab in combination with paclitaxel and carboplatin in patients with advanced nonsquamous non-small cell lung cancer (NSCLC): interim results from a randomized, open-label, phase 2 study

✍ Blumenschein, G.; Schwartzberg, L.S.; Menon, H.; Mok, T.S.K.; Stephenson, J.J.; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Treatment Rationale and Study Design for

Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

✍ Jyoti D. Patel; Philip Bonomi; Mark A. Socinski; Ramaswamy Govindan; Shengyan Ho 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 100 KB